NCT05224505View on ClinicalTrials.gov

ATA-100 (Formerly GNT0006) Gene Therapy Trial in Patients With LGMDR9

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

February 1, 2025

Study Completion Date

September 30, 2029

Conditions
LGMDR9
Interventions
BIOLOGICAL

ATA-100 (AAV9 encoding FKRP gene)

Single intravenous infusion on Day 0

Trial Locations (3)

2100

Rigshospitalet, University of Copenhagen Blegdamsvej 9, Copenhagen

75013

Institute of Myology Pitié-Salpêtrière Hospital 47 Bd de l'Hôpital, Paris

NE1 4LP

Royal Victoria Infirmary Queen Victoria Road Level 6 Leazes Wing, Newcastle upon Tyne

Sponsors
All Listed Sponsors
lead

Atamyo Therapeutics

INDUSTRY

NCT05224505 - ATA-100 (Formerly GNT0006) Gene Therapy Trial in Patients With LGMDR9 | Biotech Hunter | Biotech Hunter